1y2m

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1y2m.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:1y2m.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1y2m| PDB=1y2m | SCENE= }}
{{STRUCTURE_1y2m| PDB=1y2m | SCENE= }}
-
'''Crystal structure of phenylalanine ammonia-lyase from yeast Rhododporidium toruloides'''
+
===Crystal structure of phenylalanine ammonia-lyase from yeast Rhododporidium toruloides===
-
==Overview==
+
<!--
-
Structure-based protein engineering coupled with chemical modifications (e.g., pegylation) is a powerful combination to significantly improve the development of proteins as therapeutic agents. As a test case, phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) was selected for enzyme replacement therapy in phenylketonuria [C.R. Scriver, S. Kaufman, Hyperphenylalaninemia:phenylalanine Hydroxylase Deficiency. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, 2001, Chapter 77], an inherited metabolic disorder (OMIM 261600) causing mental retardation due to deficiency of the enzyme l-phenylalanine hydroxylase (EC 1.14.16.1). Previous in vivo studies of recombinant PAL demonstrated a lowering of blood l-phenylalanine levels; yet, the metabolic effect was not sustained due to protein degradation and immunogenicity [C.N. Sarkissian, Z. Shao, F. Blain, R. Peevers, H. Su, R. Heft, T.M. Chang, C.R. Scriver, A different approach to treatment of phenylketonuria:phenylalanine degradation with recombinant phenylalanine ammonia lyase, Proc. Natl. Acad. Sci. USA 96 (1999) 2339; J.A. Hoskins, G. Jack, H.E. Wade, R.J. Peiris, E.C. Wright, D.J. Starr, J. Stern, Enzymatic control of phenylalanine intake in phenylketonuria, Lancet 1 (1980) 392; C.M. Ambrus, S. Anthone, C. Horvath, K. Kalghatgi, A.S. Lele, G. Eapen, J.L. Ambrus, A.J. Ryan, P. Li, Extracorporeal enzyme reactors for depletion of phenylalanine in phenylketonuria, Ann. Intern. Med. 106 (1987) 531]. Here, we report the 1.6A three-dimensional structure of Rhodosporidium toruloides PAL, structure-based molecular engineering, pegylation of PAL, as well as in vitro and in vivo PKU mouse model studies on pegylated PAL formulations. Our results show that pegylation of R. toruloides PAL leads to promising therapeutic efficacy after subcutaneous injection by enhancing the in vivo activity, lowering plasma phenylalanine, and leading to reduced immunogenicity. The three-dimensional structure of PAL provides a basis for understanding the properties of pegylated forms of PAL and strategies for structure-based re-engineering of PAL for PKU treatment.
+
The line below this paragraph, {{ABSTRACT_PUBMED_16006165}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 16006165 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_16006165}}
==About this Structure==
==About this Structure==
Line 20: Line 24:
==Reference==
==Reference==
Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria., Wang L, Gamez A, Sarkissian CN, Straub M, Patch MG, Han GW, Striepeke S, Fitzpatrick P, Scriver CR, Stevens RC, Mol Genet Metab. 2005 Sep-Oct;86(1-2):134-40. Epub 2005 Jul 11. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16006165 16006165]
Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria., Wang L, Gamez A, Sarkissian CN, Straub M, Patch MG, Han GW, Striepeke S, Fitzpatrick P, Scriver CR, Stevens RC, Mol Genet Metab. 2005 Sep-Oct;86(1-2):134-40. Epub 2005 Jul 11. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16006165 16006165]
 +
 +
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase., Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR, Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2339-44. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/10051643 10051643]
[[Category: Phenylalanine ammonia-lyase]]
[[Category: Phenylalanine ammonia-lyase]]
[[Category: Rhodosporidium toruloides]]
[[Category: Rhodosporidium toruloides]]
Line 32: Line 38:
[[Category: Wang, L.]]
[[Category: Wang, L.]]
[[Category: Alpha helice]]
[[Category: Alpha helice]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 15:48:42 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 19:11:01 2008''

Revision as of 16:11, 28 July 2008

Image:1y2m.png

Template:STRUCTURE 1y2m

Crystal structure of phenylalanine ammonia-lyase from yeast Rhododporidium toruloides

Template:ABSTRACT PUBMED 16006165

About this Structure

1Y2M is a Single protein structure of sequence from Rhodosporidium toruloides. Full crystallographic information is available from OCA.

Reference

Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria., Wang L, Gamez A, Sarkissian CN, Straub M, Patch MG, Han GW, Striepeke S, Fitzpatrick P, Scriver CR, Stevens RC, Mol Genet Metab. 2005 Sep-Oct;86(1-2):134-40. Epub 2005 Jul 11. PMID:16006165

A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase., Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR, Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2339-44. PMID:10051643

Page seeded by OCA on Mon Jul 28 19:11:01 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1y2m"
Personal tools